A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Public ClinicalTrials.gov record NCT03652064. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.
Study identification
- NCT ID
- NCT03652064
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 395 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 6, 2018 (Actual)
- Primary completion
- May 7, 2024 (Actual)
- Completion
- Apr 21, 2026 (Actual)
- Last update posted
- Jun 2, 2026
2018 – 2026
United States locations
- U.S. sites
- 19
- U.S. states
- 17
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Innovative Clinical Research Inc | Cerritos | California | 90703 | — |
| Baptist MD Anderson | Jacksonville | Florida | 32207 | — |
| Fort Wayne Medical Oncology and Hematology, Inc. | Fort Wayne | Indiana | 46804 | — |
| Norton Healthcare | Louisville | Kentucky | 40207 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Boston University Medical Center | Boston | Massachusetts | 02118 | — |
| Cancer And Hematology Centers of Western Michigan PC | Grand Rapids | Michigan | 49503 | — |
| Saint Lukes Hospital Saint Lukes Cancer Specialists | Kansas City | Missouri | 64111 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| San Juan Oncology Associates | Farmington | New Mexico | 87401 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| NYU Winthrop | Mineola | New York | 11501 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Good Samaritan Hospital Corvallis | Corvallis | Oregon | 97330 | — |
| University Of Pittsburgh Medical Center UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 1301 | — |
| Gibbs Cancer Center | Spartanburg | South Carolina | 29303 | — |
| University of Texas, MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Virginia | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 95 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03652064, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 2, 2026 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03652064 live on ClinicalTrials.gov.